

From the INTERNATIONAL SEARCHING AUTHORITY

To:

**PCT**

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

(PCT Rule 43bis.1)

Date of mailing <i>(day/month/year)</i> <b>31 August 2016</b>	
Applicant's or agent's file reference <b>WXPCT160001</b>	<b>FOR FURTHER ACTION</b> See paragraph 2 below
International application No. <b>PCT/CN2016/085712</b>	International filing date <i>(day/month/year)</i> <b>14 June 2016</b>
Priority date <i>(day/month/year)</i> <b>09 March 2016</b>	
International Patent Classification (IPC) or both national classification and IPC A61F 13/15(2006.01)i; B32B 37/00(2006.01)i	
Applicant <b>JIANGSU JWC MACHINERY CO., LTD</b>	

1. This opinion contains indications relating to the following items:

- Box No. I Basis of the opinion
- Box No. II Priority
- Box No. III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- Box No. IV Lack of unity of invention
- Box No. V Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step and industrial applicability; citations and explanations supporting such statement
- Box No. VI Certain documents cited
- Box No. VII Certain defects in the international application
- Box No. VIII Certain observations on the international application

2. **FURTHER ACTION**

If a demand for international preliminary examination is made, this opinion will be considered to be a written opinion of the International Preliminary Examining Authority ("IPEA") except that this does not apply where the applicant chooses an Authority other than this one to be the IPEA and the chosen IPEA has notified the International Bureau under Rule 66.1bis(b) that written opinions of this International Searching Authority will not be so considered.

If this opinion is, as provided above, considered to be a written opinion of the IPEA, the applicant is invited to submit to the IPEA a written reply together, where appropriate, with amendments, before the expiration of 3 months from the date of mailing of Form PCT/ISA/220 or before the expiration of 22 months from the priority date, whichever expires later.

For further options, see Form PCT/ISA/220.

Name and mailing address of the ISA/	Date of completion of this opinion	Authorized officer

WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY

International application No.

PCT/CN2016/085712

## Box No. I Basis of the opinion

1. With regard to the **language**, this opinion has been established on the basis of:
  - the international application in the language in which it was filed.
  - a translation of the international application into \_\_\_\_\_ which is the language of a translation furnished for the purposes of international search (Rules 12.3(a) and 23.1(b)).
2.  This opinion has been established taking into account the **rectification of an obvious mistake** authorized by or notified to this Authority under Rule 91 (Rule 43bis.1(a)).
3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, this opinion has been established on the basis of a sequence listing filed or furnished:
  - a. (means)
    - on paper
    - in electronic form
  - b. (time)
    - in the international application as filed
    - together with the international application in electronic form
    - subsequently to this Authority for the purposes of search
4.  In addition, in the case that more than one version or copy of a sequence listing has been filed or furnished, the required statements that the information in the subsequent or additional copies is identical to that in the application as filed or does not go beyond the application as filed, as appropriate, were furnished.
5. Additional comments:

**WRITTEN OPINION OF THE  
INTERNATIONAL SEARCHING AUTHORITY**

International application No.

PCT/CN2016/085712

Box No. V	Reasoned statement under Rule 43bis.1(a)(i) with regard to novelty, inventive step and industrial applicability; citations and explanations supporting such statement		
1. Statement	Novelty (N)	Claims	1-4 None None 1-4 1-4 None
			YES NO YES NO YES NO
2. Citations and explanations :			
	[1] Cited reference document:		
	[2] Reference document D1: CN 203195856 U		
	<b>[3] Novelty:</b>		
	[4] Reference document D1 is the closest reference document and discloses a drug protection pad device (description, paragraphs [0011] - [0028], and figure 1), and discloses a method for processing a drug protection pad, involving: stirring a drug in a drug box by using a low-speed synchronous motor so that a drug powder homogeneously falls into a powder chamber, wherein the powder chamber has a stirring sheet for ensuring that the drug powder moves continuously so as to prevent the drug powder from clustering; applying the drug powder to a powder wheel, then transferring same to a drug parcel material; delivering same to drug-coating non-woven components by means of a conveyor belt; after coating, delivering same to a drug-wrapping double-ended device; delivering same to a drug parcel cutting device after hot-press adhesion, and then, the conveyor belt proceeding to a finished product bottom membrane component; after embossing a fabric single jersey with a finished product fabric single jersey embossing device, gluing same and a bottom membrane material together to wrap a formed single drug parcel inside the two, and same then proceeding to a finished product hot-press adhesion device for adhesion; cutting and shaping same by means of a finished product cutting device; folding the finished product thrice by means of a device for folding a finished product thrice; attaching a quick and easy tape product; then, arranging same by means of an arrangement wheel; and outputting the finished product through an arrangement slot after arranging same by means of a parcel arrangement and outputting device. The differences between claim 1 and reference document D1 lie in: quantitatively applying drug powder, then intermittently transferring same; delivering single jersey material using an absorption conveyor belt; gluing release paper on a bottom membrane, and recycling by means of a finished product waste recycling device. Therefore, claim 1 and its dependent claims 2-4 are novel under PCT Article 33(2).		
	<b>[5] Inventive step:</b>		
	[6] 1. Based on the distinguishing technical features determined above, the technical problem to be actually solved by claim 1 is: to improve the accuracy of adding drug powder, to prevent a piece of single jersey fabric from rolling, to improve the smoothness of a finished product; to facilitate the packaging and usage of the finished product and to increase the degree to which processing is automated. The above-mentioned distinguishing technical features are common technical means in the art. It would have been obvious to arrive at the technical solution of claim 1 on the basis of reference document D1 combined with common technical means, and therefore, claim 1 does not involve an inventive step under PCT Article 33(3).		
	[7] 2. The additional technical features of dependent claim 2 are common technical means in the art, and the additional technical features of dependent claims 3 and 4 have already been disclosed in reference document D1 (see above). Therefore, claims 2-4 also do not involve an inventive step under PCT Article 33(3).		
	<b>[8] Industrial applicability:</b>		
	[9] Obviously, the claimed drug protection pad processing method of claims 1-4 can be used in industry, and is thus industrially applicable under PCT Article 33(4).		